enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

3. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/fda-approves-first-schizophrenia...

   N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

4. Management of schizophrenia - Wikipedia

   en.wikipedia.org/wiki/Management_of_schizophrenia

   A new first-in-class antipsychotic that targets multiple neurotransmitter systems called lumateperone (ITI-007), was trialed and approved by the FDA in December 2019 for the treatment of schizophrenia in adults. [24] [26] [27] Lumateperone is a small molecule agent that shows improved safety, and tolerance.

5. Neurocrine halts development of schizophrenia drug as ... - AOL

   www.aol.com/news/neurocrine-halts-development...

   In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.

6. Ulotaront - Wikipedia

   en.wikipedia.org/wiki/Ulotaront

   The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [18] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [19]

7. Soteria (psychiatric treatment) - Wikipedia

   en.wikipedia.org/.../Soteria_(psychiatric_treatment)

   A first European near-replication of the original Soteria house was implemented in Bern, Switzerland, on May 1, 1984. However, the Bern approach differs from Mosher's original project in that it does not adopt the same anti-medical stance, using a consensual low-dose anti-psychotic treatment and including psychiatric staff.